Modality
Fusion Protein
MOA
Menini
Target
PLK4
Pathway
Cell Cycle
EoENB
Development Pipeline
Preclinical
Sep 2019
→ Jan 2028
PreclinicalCurrent
NCT08632065
1,877 pts·EoE
2019-09→TBD·Recruiting
NCT06904016
2,236 pts·NB
2019-12→2028-01·Active
4,113 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-271.8y awayInterim· NB
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
Preclinical
Recruit…
Preclinical
Active
Catalysts
Interim
2028-01-27 · 1.8y away
NB
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08632065 | Preclinical | EoE | Recruiting | 1877 | EASI-75 |
| NCT06904016 | Preclinical | NB | Active | 2236 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| ROI-3353 | Roivant Sciences | Phase 1/2 | PLK4 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 |